

HIV INFECTION

Snopková S, 4/2020

A lecture outline

- Definition
- Historical chronology
- Epidemiology
- Transmission
- Etiology
- Life cycle of HIV
- Pathogenesis
- Classification of HIV infection
 - and natural history
- Clinical manifestation of HIV infection
 - Category A – primary HIV infection
 - Category B
 - Category C – AIDS
- Laboratory tests

DEFINITION

- ***Human Immunodeficiency Virus (HIV)***
 - Infects human cells and causes gradual loss of immune system function, and these immune alterations predispose to the opportunistic infections, neoplasms, and other conditions (wasting and dementia)
- ***Human Immunodeficiency Virus infection***
 - is used to describe the cellular and humoral immunodeficiency and the numerous complications that result from the HIV infection
- ***Acquired immunodeficiency syndrome (AIDS)***
 - Is the spectrum of disorders resulting from very advanced HIV infection

HISTORICAL CHRONOLOGY


- HIV crossed from chimps to humans in the 1920s in Congo. This was probably as a result of chimps carrying the Simian Immunodeficiency Virus (SIV), a virus closely related to HIV, being hunted and eaten by people living in the area. It happened in the , people got infected from chimpanzees whose meat they ate





- HIV first began to spread along the historic trade routes of the Congo basin in the 1920s from the forest to the cities
- The area around Kinshasa is full of transport links, such as roads, railways and rivers. The area also had a growing sex trade around the time that HIV began to spread. The high population of migrants and sex trade might explain how HIV spread along these infrastructure routes.
- The first verified case of HIV is from a blood sample taken in 1959 from a man living in what is now Kinshasa in the Democratic Republic of Congo.
- The sample was retrospectively analysed and HIV detected.

Spread of HIV infection



- until the 1970s there were only sporadic unrecognized cases
- since the late 1970s, the infection has spread to all continents

1981

- AIDS was first recognized as a new and distinct clinical entity
- AIDS was first reported in previously healthy men
 - Gottlieb and Friedman reported initial cases of Kaposi's sarcoma and *Pneumocystis carinii jiroveci* pneumonia in previously healthy men

1982

- CDC created first definition of AIDS

1983

- a new retrovirus (later called HIV-1) was identified and described as the causative agent of AIDS (formerly HTLV III/LAV)

1985

- first antiretroviral drug was discovered (zidovudine - ZDV, formerly AZT)

1986

- International committee adopted the name *Human immunodeficiency virus* (HIV-1)
- Montagnier discovered HIV-2

HIV-1 subtypes

The most common causes of HIV disease throughout the world is HIV-1, which comprises several subtypes with different geographic distribution

- Geographic distribution
 - A – Central and East Africa, East Europe
 - B – America & Europe
 - C – South Africa & India, Brazil
 - D – Central, East and South Africa
 - E – Tchaj-wan & India
 - F – Romania & Brazil
 - G, H, O – Western Africa

1987

- the first drug for clinical use NRTI – AZT (later ZDV)

1991-1994

- next NRTIs (didanosine, zalcitabine, stavudine, lamivudine...)

1995

- the first protease inhibitor was approved for clinical use

1996 – HAART era

- the introduction of HIV therapy into clinical practice represented a significant step forward in the treatment of HIV infection
- the ability of HAART regimens have transformed HIV infection into a manageable chronic disease in many patients

HAART = cART = OBT = ART

Three-drug combinations are currently recommended for the initiation of treatment in all patients

HAART – Highly Active AntiRetroviral Therapy

cART - Combination AntiRetroviral Therapy

OBT - Optimalising Basic Treatment

ART - AntiRetroviral Therapy

- Enormous changes in prognosis of HIV/AIDS disease
 - maximally and durably supresses viral load
 - restores immunological function
 - improves quality of life
 - dramatically reduces HIV-related morbidity and mortality


Epidemiology

HIV – a global health crisis

- Since AIDS was recognized as a distinct disease in 1981, **the catastrophic nature of this pandemic** has been recognized and more fully characterized
- Since the beginning of this pandemic
 - **over 78 million** individuals worldwide have been infected by HIV-1
 - **over 40 million** people died
- Number of people living with HIV/AIDS is increasing


Summary of the global HIV epidemic (2018)

37.9 million
people living with HIV
[32.7 million – 44.0 million]



1.7 million
people newly infected
[1.4 million – 2.3 million]

New HIV infections, or “HIV incidence,” refers to the estimated number of people who newly acquired the HIV virus during a year, which is different from the number of people *diagnosed* with HIV during a year. Some people may have HIV but not know it



0.8 million
HIV-related deaths
[0.6 million – 1.1 million]

Source: UNAIDS/WHO estimates




World Health
Organization

AIDS by the numbers

- ↓ 35% decrease in new HIV infection since 2000
- ↓ 42% decrease in AIDS-related deaths since the peak in 2004
- ↓ 58% decrease in new HIV infections among children since 2000
- ↑ 84% increase in access to antiretroviral therapy since 2010

Decline in HIV incidence and mortality over time




- the highest incidence of HIV infection was in 1997
- 3,5 mil people were infected during 1997
- the highest mortality due to HIV infection was in 2004
- 2,0 mil people died due to HIV during 2004




World Health
Organization

Global number of people newly infected with HIV








Source: UNAIDS/WHO estimates

Global number of HIV-related deaths




Source: UNAIDS/WHO estimates

Summary of the global HIV epidemic (2018)

	People living with HIV in 2018	People newly infected with HIV in 2018	HIV-related deaths 2018
 Total	37.9 million [32.7 million – 44.0 million]	1.7 million [1.4 million – 2.3 million]	770 000 [570 000 – 1.1 million]
 Adults	36.2 million [31.3 million – 42.0 million]	1.6 million [1.2 million – 2.1 million]	670 000 [500 000 – 920 000]
 Women	18.8 million [16.4 million – 21.7 million]	–	–
 Men	17.4 million [14.8 million – 20.5 million]	–	–
 Children (<15 years)	1.7 million [1.3 million – 2.2 million]	160 000 [110 000 – 260 000]	100 000 [64 000 – 160 000]

Source: UNAIDS/WHO estimates

The highest incidences of infection




The vast majority of people with HIV are in low- and middle-income countries.

- 20.6 million people with HIV (57%) in eastern and southern Africa,
- 5.0 million (13%) in western and central Africa
- 5.9 million (16%) in Asia and the Pacific
- 2.2 million (6%) in Western and Central Europe and North America

People living with HIV by WHO region (2018)

37.9
million
people living
with HIV globally



Source: UNAIDS/WHO estimates




World Health
Organization

New HIV diagnoses,

EU/EEA



Rate per 100 000 population




EU/EEA rate: 5.9 per 100 000*


Non-visible countries



Source: ECDC/WHO (2017). HIV/AIDS Surveillance in Europe 2017–2016 data
* adjusted for reporting delay



Percentage of adults (15+) living with HIV who are female




HIV+ female

- **In total > 52%**

- **In Sub-Saharan
Africa > 62%**



more HIV+ children



TRANSMISSION

HIV has been isolated from bodily fluids

With high/titer viremia

- **blood**
- **semen**
- **cervicovaginal secretion**

**These bodily fluids have been implicated
in the transmission of HIV**

With low/titer viremia


- **saliva**
- **tears**
- **urine**
- **CSF**

**These bodily fluids have not been implicated
in the transmission of HIV**

Modes of HIV transmission

**HIV is transmitted through
three primary routes:**

- 1. sexual**
- 2. parenteral**
- 3. vertical**



1. Sexual rout

Sexual contact with an infected person is the predominant mode of transmission worldwide (> 95 % of HIV infection)

- **Heterosexual intercourse**
 - The dominant mode (90%) worldwide
- **Homosexual intercourse (MSM)**
 - Men who have sex with man
 - Homosexual and bisexual men
 - The main mode in North America, Europe and Australia



2. Parenteral rout (exposure)



1. Blood transfusion and blood products can be infected by HIV

- recipients are in risk acquiring of HIV
- hemophiliacs, plasma, clotting factors, whole blood, blood cellular components, recipients of tissue, organ transplants, semen

Transfusion of infected blood or blood components

- as a risk factor for acquiring HIV has dramatically decreases in incidence
- secondary to the availability of a screening of all blood products since 1987

2. Parenteral rout (exposure)



2. Contaminated injection and medical equipments

- Drug users, sportman
- Nosocomila
- Health and laboratory workers...

2. Parenteral rout (exposure)



The probability transmission of HIV infection **after skin puncture** with infected materials depends on multiple factors

- High titer viremia of the patients
- Amount of blood on the needle
- Advanced HIV infection...

Without antiretroviral therapy

is estimated to be **0.3 – 0.5%**

2. Parenteral rout (exposure)




Postexposure prophylaxis (PEP)

In case of skin puncture with infected materials

- Prompt administration of a combination regiment of ART drugs (PEP)
- Significantly decreases the likelihood of HIV infection following needle-stick injuries

3. Vertical rout (mother-to-child)



Perinatal transmission may occur

1. **During pregnancy** (in utero)
2. **During delivery** (at birth, intrapartum)
3. **During breastfeeding**


Perinatal transmission rates range

- from 22 to 46% (without ART)

In Europe and North America

- from 15 to 25% before ART

3. Vertical rout (mother-to-child)




Maternal ART has been shown to decrease vertical transmission dramatically

- in Europe and North American countries
< 1,5% of all newborns

In 2018

- 92% of pregnant women with HIV received ART to prevent transmitting HIV to their babies during pregnancy and childbirth and to protect their own health.
- This is compared to 49% in 2010.


3. Vertical rout (mother-to-child)



Decreasing mother-to-child transmission

- Use of ART by the mother and use of AZT by the infant after delivery
- Cesarean section
- Avoidance of breastfeeding

3. Vertical rout (mother-to-child)



Breastfeeding is very important for HIV transmission. Risk breastfeeding is about 10%.

Factors thought to increase risk of mother-to-child transmission

- High maternal viral load and no ART
- Prolonged membrane rupture
- Natural delivery
- Prematurity of newborn
- Low birth weight of newborn
- breastfeeding

No transmission

- **Household contacts** not sexually involved with infected persons **are not risk** for acquiring HIV
- **Family members** who shared bathrooms and eating utensils with HIV+ patients **did not become infected**
- **Mosquitoes do not transmit HIV**
- **No cases** of transmission from **human bites** have been reported.

Saliva contains neutralizing factors.

ETIOLOGY

HIV

- belongs to the family of human retroviruses and the subfamily of lentiviruses


HIV = causativ agent

Family: *Retroviridae*

Genus: *Lentivirus*


HIV-1, HIV-2

SIV...




Virion structure

– very important the main structures of virus



**Free virus
and possibly virus-infected cells
enter the blood
during initial infection**

**The HIV envelope
glycoprotein 120
have a high affinity
for the CD4 molecule (receptors)
on the surface of CD4 cells
(helper cells, Th lymphocytes)**





Life cycle of HIV

1. Adsorption to CD4+ cell cereptor (and coreceptors)

2. After HIV binds to CD4 receptor, the viral and cellular membranes fuse and the HIV nucleoprotein complex enters the cytoplasm

3. Uncoating follows
– into the host cells





4. Using its retroviral reverse transcriptase, the HIV initiates viral DNA synthesis, using its own RNA as a template

5. The double-stranded viral DNA enters into the nucleus of host cell

6. Integration of the DNA into host chromosome is catalyzed by integrase (another retroviral enzyme)


7. When a CD4 cell with integrated provirus (DNA) is activated, retroviral synthesis is begun, directed by the cell's infected DNA

8. Synthesis of viral proteins is started


9. Mature viral cores are produced through action on viral protease (another retroviral enzyme)

10. New viral particles are produced by budding at the cell plasma membrane

11. The complete virus is extruded into the bloodstream



Electron micrograph of HIV budding from a CD4+ cell,
The complete virus is extruded into the bloodstream




PATHOGENESIS

Free virus
and possibly virus-infected cells
enter the blood during initial infection


- The HIV envelope glycoprotein 120 have a high affinity for the CD4 molecule (receptor) on the surface of CD4 cells (helper cells, Th lymphocytes)

- Productive viral replication is lytic to infected T cells

- Loss of number of CD4 cells is basis of advanced infection



CD4+ lymphocytes and HIV



**A decrease in function
as well as number
of CD4 cells
is central
to the immune
dysfunction**

CD4+ lymphocytes depletion – gradual loss of number of CD4 cells is basis of advanced infection

CD4+
count

primary HIV infection

asymptomatic infection

early symptomatic infection

late symptomatic infection


final stadium

500/mm³

200/mm³

50/mm³

years



HIV infects

- monocytes, macrophages, B cells
- dendritic cells, Langerhans cells in GI
- bone marrow cells, myocardial cells...

Infection by HIV into many cells may contribute greatly to **various clinical syndromes** of HIV infection and AIDS

Other host cells

- also are infected by HIV
- these cells **do not appear to be lysed** by the virus
- cells that do not express CD4 receptor can also be infected by HIV (mechanisms are unknown)

Classification of HIV infection

In 1993 the CDC issued a revised classification system for HIV
CDC – Centers for Disease Control
and Prevention, Atlanta, USA

Criteria for HIV infection for adult person include:


- laboratory categories
- clinical categories

Laboratory categories

- The three categories corresponding to **CD4+ lymphocyte counts**
- The **percentage of CD4+ lymphocyte** also can be use
- Normal values are a mean of **800 to 1050 cells per μl (mm^3)**

Laboratory category	CD4+ T-cell count	%
1	$\geq 500/\text{mm}^3$	$\geq 29\%$
2	200 - 499/mm^3	14-28%
3	$< 200/\text{mm}^3$	$< 14\%$

CD4+ lymphocytes depletion – gradual loss of number of CD4 cells over time



Clinical categories

– corresponding to clinical condition


- A**
- acute primary HIV
 - asymptomatic infection
 - persistent generalized lymphadenopathy (PGL)

is not typically associated with OI

Risk for OI begins

- B**
- symptomatic infection (not A or C condition)
- C**
- AIDS indicator condition

CD4+ lymphocytes depletion – gradual loss of number of CD4 cells over time



These variants of laboratory and clinical categories are possible.

Laboratory categories

Clinical categories

**CD4+ T-cell
categories**

**A
asymptomatic,
acute(primary)
HIV or PGL**

**B
symptomatic,
not A or C
conditions**

**C
AIDS
-indicator
conditions**

1

$\geq 500/\text{mm}^3$

A1

B1

C1

2

$200-499/\text{mm}^3$

A2

B2

C2

3

$< 200/\text{mm}^3$


A3

B3

C3

Natural course of HIV infection (without treatment)

- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)



CD4 = immunological mark; VL = virological mark


Category A

- Consists of one or more of the following conditions in an adolescent or adult with documented HIV infection
- Conditions listed in categories B and C must not have occurred

Includes:

- ◆ Acute (primary) HIV infection
- ◆ Asymptomatic HIV infection
- ◆ Persistent generalized lymphadenopathy (PGL)

CD4+ lymphocytes depletion




Acute primary HIV infection (mononucleosis-like syndrome, acute retroviral syndrom)

Occurs:

- up to 70% of HIV-infected persons
- between 2 and 8 weeks after initial infection
- acute symptoms last 3 days to 3 weeks
- a variety of nonspecific signs and symptoms have been associated with the acute retroviral syndrome

Natural course of HIV infection (without treatment)


- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)



Natural course of HIV infection (without treatment)

- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)

Acute infection



- Usually 2 to 8 weeks after infection
- Production of **antibodies** to HIV is started (time of seroconversion)
- Significant but **transient fall in CD4 cells count**
- **Wide dissemination of virus**
- Symptoms include a glandular fever-like illness with fatigue, fever lymphadenopathy and seroconversion rash...
- **Most individuals have no symptoms**

Signs and symptoms of primary HIV infection

A variety of nonspecific signs and symptoms have been associated with the acute retroviral syndrome

- ◆ Fever 77%
- ◆ Lethargy/ fatigue 66%
- ◆ Rash 56%
- ◆ Myalgia 55%
- ◆ Headache 51%
- ◆ Pharyngitis 44%
- ◆ Cervical adenopathy 39%
- ◆ Arthralgia 31%
- ◆ Oral ulcer 29%
- ◆ Pain on swallowing 28%
- ◆ Axillary adenopathy 24%

Acute primary HIV infection

Rash on the back



Seborrhoeic dermatitis



Acute primary HIV infection

Herpetic gingivitis – oral ulcer
(trush)



Herpetic gingivitis



◆ Weight loss	24%
◆ Nausea	24%
◆ Diarrhea	23%
◆ Night sweats	22%
◆ Cough	22%
◆ Anorexia	22%
◆ Abdominal pain	19%
◆ Oral candidiasis	17%
◆ Vomiting	12%
◆ Photophobia	12%
◆ Meningitis	12%
◆ Genital ulcer	7%
◆ Tonsillitis	7%
◆ Depression	7%
◆ Dizziness	6%

Laboratory – in primary HIV infection

- **Lymphopenia**
- **Transient decrease of CD4+ lymphocyte count**
- **p24 – HIV core antigen**
 - may be detected in serum and CSF
within 2 weeks of exposure to HIV
and may persist for weeks or months
- **anti-HIV**


antibodies to HIV usually are detected within 2 months after HIV exposure not within primary HIV infection

Asymptomatic HIV infection

- **the vast majority of individuals infected with HIV are asymptomatic**
- **this asymptomatic state may be prolonged**
- **this period of latency is, in fact, a time of intense viral replication and immune response**

Natural course of HIV infection (without treatment)

- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)




Viral load (VL) = the number of copies of RNA HIV-1 per 1 ml of plasma

Natural course of HIV infection (without treatment)

- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)

Acute infection Latency phase – clinical asymptomatic phase




- May last for approxim. 10 years
- This not a period of virological and immunological latency
- **CD4 cell counts** gradually **fall** over time
- Immune system weakens as **viral load increases**

Predictors of HIV-disease progression

clinical	immunological	virological
<ul style="list-style-type: none">• oral candidiasis• involution of PGL• constitutional symptoms (fever, night sweats, weight loss...)	<ul style="list-style-type: none">• ↓ CD4+ cell count• ↑ β-2-microglobulin• ↑ neopterin	<ul style="list-style-type: none">• ↑ viral load• ↑ p24 antigen


**CLINICAL
CATEGORY B**

CD4+ lymphocytes depletion



Natural course of HIV infection (without treatment)

- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)



• **CD4 cell counts fall**

• **Viral load increases**

• Immune system weakens

• Clinical symptoms begin to appear

Category B



= symptomatic HIV infection

- **Consists of symptomatic conditions in an HIV-infected adolescent or adult that are not included among conditions listed in clinical category C**
- **Examples of conditions in clinical category B include:**
 - **Fever of >38.5 C > 1 month**
 - **Diarrhea > 1 month**


Clinical category B

Oropharyngeal candidosis on the bucal mucosa, on the tongue...

Oropharyngeal candidosis on the palatum



Esophageal candidosis



Endoscopic picture

- **Vulvovaginal candidosis**
- **Lymphoid interstitial pneumonitis (LIP)**
- **Cervical dysplasia or carcinoma in situ**
- **Pelvic inflammatory disease (PID)**
- **Listeriosis**
- **Bacillary angiomatosis**
- **Trombocytopenia**
- **Peripheral neuropathy**

Clinical category B

Bacillary angiomatosis (*Bartonella henselae*, *Bartonella quintana*)



Oral hairy leucoplacia
(cobblestone tongue)



Herpes zoster recurrent or multidermatomal



Clinical category C - AIDS


- Is the end stage of long-standing, chronic infection with HIV
- Without antiretroviral therapy, approximately 50% of individuals develop AIDS within 10 years after HIV infection

The AIDS syndrome is defined by various

- opportunistic infections
- malignancies
- other conditions


sumarized in the CDC definition.

CD4+ lymphocytes depletion



Natural course of HIV infection (without treatment)


- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)



- **VL is extremely high** – possibly one million copies/ml or more
- **CD4 counts** usually **below 200** cells/mm³ and may fall **to zero**

Natural course of HIV infection (without treatment)

- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)



- Symptoms of very advanced infection include opportunistic infections, malignancies and other clinical conditions such as AIDS case definition



Category C - AIDS


- **Includes the following clinical conditions as listed in the AIDS case definition**
- **For classification purposes, once a category C conditions has occurred, the person will remain in category C untill the end of his life**

Opportunistic infections - Such as AIDS case definition

Pneumocystis jiroveci pneumonia – High-resolution CT scan

- Showing ground-glass appearance (image of milk glass)
- Destruction of pulmonary parenchyma (HRCT) scan in 32-year-old woman with HIV infection showing ground-glass appearance due to *Pneumocystis jiroveci* pneumonia.
- CD4+ 4/ μ l
- *Jirovecii* > 100 000 000 kopií DNA/rekaci





Pneumocystis jirovecii pneumonia (PCP)
showing ground-glass appearance

P. jirovecii

CD4 lymf. 2 bb/mm³

VL 468000 kopií/ml




AIDS – Opportunistic infections

- Candidiasis esophageal, tracheal, bronchial or pulmonary
- Herpes simplex with mucocutaneous ulcer > 1 month
- Herpes simplex esophagitis, bronchitis, pneumonia
- Recurrent pneumonia with > 2 episodes in 12 month
- Recurrent *Salmonella* bacteremia
- Chronic intestinal cryptosporidiosis (diarrhea > 1 month)
- Extrapulmonary cryptococcosis
- CMV retinitis
- Generalized CMV infection (in other organ than liver, spleen, nodes)

Severe perianal aciclovir-resistant herpes simplex virus 2 infection


a-untreated appearance

b-healing and re-epithelialization after treatment with foscarnet and institution of HAART




AIDS – clinical category C

Herpes simplex esophagitis



CMV retinitis



AIDS

- **Extrapulmonary cryptococcosis**
- on the skin with cryptococcomas



Cryptococcus neoformans
in cerebrospinal fluid


AIDS – Opportunistic infections

- Disseminated or extrapulmonary histoplasmosis
- Disseminated coccidioidomycosis
- Tuberculosis
(pulmonary or extrapulmonary)
- Disseminated or extrapulmonary *M. avium* or *M. kansasii* infection
- And others...

Malignancies – AIDS case definition

- **Kaposi's sarcoma**
- **Lymphoma**
 - ◆ **Burkitt's**
 - ◆ **Non-Hodgkin lymphoma**
 - ◆ **Primary lymphoma in brain**
- **Invasive cervical cancer**

Multiple lesions of Kaposi's sarcoma



Non-Hodgkin lymphoma (AIDS - category C)



Other conditions – such as AIDS case definition

- **HIV encephalopathia (dementia)**
- **Wasting syndrome („slim“ disease)**
 - **the introduction of ART has decreased the incidence of opportunistic infections and associated wasting**
 - **wasting still remains a common problem in clinical practice**
 - **especially in middle income countries**

Wasting syndrome associated with HIV/AIDS („slim disease“)



HIV-associated wasting syndrome, „**slim disease**“

- Loss of body weight together with fever or diarrhea for more than 30 days
- In patient at the time of advanced infection
- In up to 50% of patients in Africa (less in industrialized countries)

Key etiologic factors

- Basal metabolic rate is generally increased at all stages of HIV infection
- Disturbances in intermediary metabolism
- A reduction in energy intake (nausea, taste disturbance, dysphagia, early satiety, depression, dementia...)
- Malabsorption – idiopathic (HIV enteropathy)
 - secondary (GI pathogens, OI)

Opportunistic infection in GIT

- Protozoa (cryptosporidia, microsporidia...)
- Bacteria (*Shigella* spp., *Salmonella* spp., *Campylobacter* spp.,...)

Profound anorexia

mediated by cytokine release

accompanies acute OI (not only in GIT)

and results in rapid weight loss.


Main laboratory tests for dg.

■ **Recommended for initial evaluation
and follow-up of all patients**

1. **Anti-HIV** (antibodies to HIV)
ELISA, WB
2. **Viral load** (the number of copies
of RNA HIV-1)
3. **CD4+ lymphocyte count**

1. Anti – HIV


- ◆ **enzyme-linked immunosorbent assay (ELISA)**
 - ◆ **antibodies to HIV**
 - ◆ **standard test**
 - ◆ **primary screening test for HIV infection**
- ◆ **WB (Western Blot)**
 - ◆ **if the ELISA anti-HIV test is reactive, WB is done**
 - ◆ **more specific, less sensitive**



Anti-HIV

- Approximately 79% of people with HIV globally knew their HIV status.
- The remaining 21% (about 8.1 million people) still need access to HIV testing services.
- Testing is an essential gateway to HIV prevention, treatment, care and support services.

2. VL – viral load (viral detection)



RNA HIV-1 PCR

- quantitative plasma RNA HIV-1
- the number of copies of RNA HIV-1 per 1 ml plasma
- by technique PCR
- main virological marker
- the most reliable indicator of prognosis

Quantitative HIV RNA (VL) is useful for:


- Diagnosis acute HIV infection
- For predicting probability of transmission
- Predicting the rate of progression in chronically infected patients
- For therapeutic monitoring
- is very sensitive
- was developed for monitoring the progression of the disease and the effectiveness of antiretroviral therapy
- is not for establishing the diagnosis of HIV infection
- should be repeated from 3- to 4-month intervals during therapy
- In stable patients it should be repeated every 6 months

ART

- The objective of ART should be to maintain the lowest VL for as long as possible
- When an effective AR regimen is initiated in an asymptomatic patient with no previous ART, the VL should decrease to an undetectable level (< 50 copies/ml) within 24 weeks

Natural course of HIV infection

- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)



VL is extremely high (possibly one million copies/ml and more)

- Primoinfection
- Advanced infection - AIDS

3. CD4+ Cell (lymphocyte) Count


This is a standard test:

- to assess prognosis for progression infection
- to formulate the differential diagnosis in a symptomatic patient
- to make therapeutic decisions regarding antiviral treatment and prophylaxis for opportunistic pathogens

- It was the most reliable indicator of prognosis until recently
- Number of copies RNA HIV (VL) is considered the most reliable indicator of prognosis currently

Natural course of HIV infection

- Gradual loss of number of CD4 cells over time
- Gradual increase of number of viral copies (increase of viral load)



Another screening laboratory tests

- ◆ Complete blood count
- ◆ Serum chemistry panel
- ◆ Urine
- ◆ Syphilis serology
- ◆ Screening for other sexually transmitted diseases
- ◆ Tuberculin skin test (Mantoux)
- ◆ Serology
 - Hepatitis A, B, C, D, E
 - Toxoplasmosis
 - CMV
- ◆ Chest X-ray
- ◆ EKG
- ◆ Glucose-6-phosphate dehydrogenase levels (G6-PD)

Glucose-6-phosphate dehydrogenase deficiency

- **is a genetic disease that predisposes to hemolytic anemia following exposure to oxidant drugs**
 - ◆ **Dapsone (x lepra, sec.prof. PCP)**
 - ◆ **Primaquine (x malaria, PCP)**
 - ◆ **TMP-SMX... (x PCP)**
- **Is found in 10% of black men and in 1% to 2% of black women, in men from Mediterranean area, India and Southeast Asia**

Thank you for your attention...